High Level Activity of Recombinant Lysostaphin After Computer Simulation and Additive-Based Refolding
- 35 Downloads
Lysostaphin is a peptidoglycan hydrolase, produced by Staphylococcus simulans, which has illustrated significant bactericidal activities against Staphylococcus aureus species. Currently, recombination is the common approach of lysostaphin production. However, the recombinant produced lysostaphin shows weak antibacterial activities. The reason can be the aggregation of produced lysostaphin which leads to the destruction of natural protein folding. The most common strategy providing the best situation for correct refolding of the recombinant protein is dialysis. In this study, based on the computer simulations different condition of dialysis was applied to achieve the most significant antibacterial activity. In this study, lysostaphin was expressed in Escherichia coli (E. coli) BL21 (DE3) pLysS cells and purified by affinity chromatography. Various dialysis methods were employed to enable the protein to refold to its natural form. The results of final protein antibacterial activity evidenced the high efficiency of computer simulations estimation ability in predicting best dialysis buffer according to the interaction between protein and buffer additive compounds. Finally, it was confirmed that the buffer containing proline 0.15 M and glucose 0.2 M caused the best lysostaphin refolding. Employing computer simulation before initiating the dialysis process would be a novel efficient and economic pathway of protein folding recovery.
KeywordsComputer simulation Lysostaphin Protein refolding Recombinant protein Staphylococcus aureus
This Study was conducted with financial assistance from Arak University of Medical Sciences, Iran, and the authors are grateful for the university’s invaluable contribution to this study.
This study was emanated from a proposal (No: 1379) approved and supported by Arak University of Medical Sciences, Iran. This study was approved by the ethics committee of Arak University of Medical Sciences, Arak, Iran, Ethics code: 91-128-6.
Compliance with Ethical Standards
Conflict of interest
The authors declare that no conflict of interest exists.
- Abbasian SS, Ghaznavi Rad E, Akbari N, Zolfaghari MR, Pakzad I, Abtahi H (2015) Overexpression and enzymatic assessment of antigenic fragments of hyaluronidase recombinant protein from Streptococcus pyogenes. Jundishapur J Microbiol 8(1):e13653-e13653Google Scholar
- Caffery ML, Dobosh PA, Richardson D (1998) Laboratory exercises using HyperChem. Hypercube, GainesvilleGoogle Scholar
- Dajcs JJ, Hume EB, Moreau JM, Caballero AR, Cannon BM, O’Callaghan RJ (2000) Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit. Investig Ophthalmol Vis Sci 41(6):1432–1437Google Scholar
- Palmer I, Wingfield PT (2004) Preparation and extraction of insoluble (inclusion-body) proteins from Escherichia coli. Curr Protocols Protein Sci 6.3(1–6.3):20Google Scholar
- Waitz JA (1990) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. National Committee for Clinical Laboratory Standards, VillanovaGoogle Scholar